Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy … Read more
Beijing Scitop Bio Tech Co Ltd - Asset Resilience Ratio
Beijing Scitop Bio Tech Co Ltd (300858) has an Asset Resilience Ratio of 36.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Beijing Scitop Bio Tech Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Beijing Scitop Bio Tech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥717.09 Million | 36.95% |
| Total Liquid Assets | CN¥717.09 Million | 36.95% |
Asset Resilience Insights
- Very High Liquidity: Beijing Scitop Bio Tech Co Ltd maintains exceptional liquid asset reserves at 36.95% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Beijing Scitop Bio Tech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Scitop Bio Tech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Beijing Scitop Bio Tech Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Scitop Bio Tech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.49% | CN¥296.73 Million | CN¥1.92 Billion | -19.61pp |
| 2023-12-31 | 35.10% | CN¥635.26 Million | CN¥1.81 Billion | +19.39pp |
| 2022-12-31 | 15.70% | CN¥281.17 Million | CN¥1.79 Billion | +6.91pp |
| 2021-12-31 | 8.80% | CN¥91.55 Million | CN¥1.04 Billion | -8.06pp |
| 2020-12-31 | 16.85% | CN¥168.40 Million | CN¥999.25 Million | -- |